152 related articles for article (PubMed ID: 38696747)
1. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
Huntington SF; Cheng WY; Sarpong EM; Leng S; Farooqui MZH; Agu US; Catillon M; Lejeune D; Downes N; Matay L; Duh MS; De Nigris E
Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38696747
[TBL] [Abstract][Full Text] [Related]
2. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
Ann Hematol; 2023 Oct; ():. PubMed ID: 37843620
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Nguyen TT; Thanh Nhu N; Tran VK; Van Cau N; Lin CF
J Immunother; 2023 Oct; 46(8):299-309. PubMed ID: 37216406
[TBL] [Abstract][Full Text] [Related]
5. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.
Bennett R; Anderson MA; Seymour JF
J Hematol Oncol; 2023 Jul; 16(1):72. PubMed ID: 37422670
[TBL] [Abstract][Full Text] [Related]
6. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
JCO Oncol Pract; 2024 Apr; ():OP2300630. PubMed ID: 38626366
[TBL] [Abstract][Full Text] [Related]
7. [Immune Reconstitution after BTKi Treatment in Chronic Lymphocytic Leukemia].
Wang YL; Tang PX; Chen KL; Guo GY; Long JL; Zou YQ; Liang HY; Xu ZS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):1-5. PubMed ID: 38387891
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of "accelerated" chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.
Xie J; Jang A; Vegel A; Hajja Y; Mouawad Y; Baghian A; Berbari B; Schmid JL; Socola F; Safah H; Saba NS
Leuk Res Rep; 2021; 15():100247. PubMed ID: 34040961
[TBL] [Abstract][Full Text] [Related]
9. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
10. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Easaw S; Ezzati S; Coombs CC
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):697-704. PubMed ID: 37544810
[TBL] [Abstract][Full Text] [Related]
11. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Wiśniewski K; Puła B
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284
[TBL] [Abstract][Full Text] [Related]
12. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
13. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
St-Pierre F; Ma S
Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Wolska-Washer A; Robak P; Witkowska M; Robak T
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):207-224. PubMed ID: 38516702
[TBL] [Abstract][Full Text] [Related]
15. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
17. Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study.
Eyre TA; Hess LM; Sugihara T; He D; Khanal M; Pagel JM; Walgren RA; B Abada P; Konig H; Roeker LE; Mato A
Leuk Lymphoma; 2023 May; 64(5):1005-1016. PubMed ID: 36987650
[TBL] [Abstract][Full Text] [Related]
18. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Hatashima A; Karami M; Shadman M
Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.
Nguyen TT; Nhu NT; Tran VK; Viet-Nhi NK; Ho XD; Jhan MK; Chen YP; Lin CF
Sci Rep; 2023 Jun; 13(1):9775. PubMed ID: 37328530
[TBL] [Abstract][Full Text] [Related]
20. Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
Tomasulo E; Paul S; Mu R; Tian X; Chen J; Pleyer C; Wiestner A; Sun C
Leuk Lymphoma; 2023 Dec; 64(14):2306-2315. PubMed ID: 37732614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]